Carol Waghorne

2.4k total citations · 1 hit paper
29 papers, 2.1k citations indexed

About

Carol Waghorne is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Carol Waghorne has authored 29 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Carol Waghorne's work include Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Bacteriophages and microbial interactions (3 papers). Carol Waghorne is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Bacteriophages and microbial interactions (3 papers). Carol Waghorne collaborates with scholars based in Canada, United States and United Kingdom. Carol Waghorne's co-authors include Martin L. Breitman, Robert S. Kerbel, James W. Dennis, Suzanne Laferté, Bruce R. Zetter, A. Lagarde, Peeyush K. Lala, Simcha Yagel, Brian Schwartz and B E Elliott and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Carol Waghorne

27 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

β1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis

1987 819 citations James W. Dennis, Suzanne Laferté et al. Science profile →

Peers

Countries citing papers authored by Carol Waghorne

Since Specialization

Citations

This map shows the geographic impact of Carol Waghorne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Waghorne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Waghorne more than expected).

Fields of papers citing papers by Carol Waghorne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Waghorne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Waghorne. The network helps show where Carol Waghorne may publish in the future.

Co-authorship network of co-authors of Carol Waghorne

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Waghorne. A scholar is included among the top collaborators of Carol Waghorne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Waghorne. Carol Waghorne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract A278: ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models. 2013 ·Molecular Cancer Therapeutics ·Daniel T. Dransfield, Jennifer Lee, Carol Waghorne, Cathy Bull, Ronald E. Savage, Xiaolan Zhao, (unknown), Edward Chang, (unknown), Sudharshan Eathiraj, Susan Cornell-Kennon, Xiubin Gu, Syed Muhammad Adnan Ali, Chang-Rung Chen	4
2	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors 2012 ·Cancer ·Andrew J. Wagner, John M. Goldberg, Steven G. DuBois, Edwin Choy, Lee S. Rosen, Alberto S. Pappo, James I. Geller, Ian Judson, David Hogg, Neil Senzer, Ian J. Davis, Feng Chai, Carol Waghorne, Brian Schwartz, George D. Demetri	118
3	Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential 2012 ·Clinical & Experimental Metastasis ·Mark F. Coughlin, Diane R. Bielenberg, Guillaume Lenormand, Marina Marinkovic, Carol Waghorne, Bruce R. Zetter, Jeffrey J. Fredberg	98
4	Abstract 1729: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study 2012 ·Cancer Research ·Scott J. Rodig, Lecia V. Sequist, Joan H. Schiller, (unknown), (unknown), Carol Waghorne, Hamim Zahir, Brian Schwartz	8
5	Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases. 2011 ·Molecular Cancer Therapeutics ·Thomas Chan, Jean‐Marc Lapierre, Mark A. Ashwell, Dennis S. France, Chang-Rung Chen, Susan Cornell-Kennon, Cathy Bull, (unknown), Rocio Palma, Yanbin Liu, Sapna Makhija, Carol Waghorne, (unknown), Kôsaku Fujiwara	3
6	Abstract 3571: Exploratory biomarker discovery for clinical development of ARQ 087, a potent pan-FGFR kinase inhibitor 2011 ·Cancer Research ·Yi Yu, Xiubin Gu, (unknown), Xiaolan Zhao, Edward Chang, (unknown), (unknown), Laura A. Cousens, Cathy Bull, Yunxia Wang, (unknown), Carol Waghorne, Chang-Rung Chen, Dennis S. France, Edwin Clark, Thomas Chan	1
7	A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors 2011 ·Clinical Cancer Research ·Lee S. Rosen, Neil Senzer, Tarek Mekhail, Ram Ganapathi, Fang Chai, Ronald E. Savage, Carol Waghorne, Giovanni Abbadessa, Brian Schwartz, Robert Dreicer	76
8	Abstract 2517: Pharmacodynamic biomarkers for ARQ 736, a small molecule BRAF inhibitor 2010 ·Cancer Research ·(unknown), Xiaolan Zhao, Xiubin Gu, Edward Chang, Laura A. Cousens, (unknown), (unknown), Yanbin Liu, Cathy Bull, Carol Waghorne, Thomas Chan	5
9	Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells 2010 ·Proceedings of the National Academy of Sciences ·Nish Patel, Sabarni K. Chatterjee, Vladimir Vrbanac, Ivy Chung, (unknown), Rachelle R. Olsen, Carol Waghorne, Bruce R. Zetter	83
10	Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition 2009 ·Journal of Clinical Oncology ·Tami Yap, Sophia Frentzas, Nina Tunariu, Jorge Barriuso, (unknown), Michael Germuska, Carol Waghorne, (unknown), Nandita M. deSouza, Johann S. de Bono	13
11	Abstract B117: Expression of c-MET and related oncogenic signals in formalin-fixed paraffin-embedded human tumors 2009 ·Molecular Cancer Therapeutics ·Laura A. Cousens, Carol Waghorne, Scott J. Rodig, Xiubin Gu, Xiaolan Zhao, Yi Yu, Edward Chang, Thomas Chan	1
12	Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism 2006 ·Journal of Cell Science ·Seung‐Whan Kim, Ursula Mangold, Carol Waghorne, Arian Mobascher, Lisa M. Shantz, (unknown), Bruce R. Zetter	47
13	Persistence of Ha-ras-induced metastatic potential of SP1 mouse mammary tumors despite loss of the Ha-ras shuttle vector. 1992 ·Proceedings of the National Academy of Sciences ·(unknown), Carol Waghorne	7
14	Clonal selection within metastatic sp1 mouse mammary tumors is independent of metastatic potential 1991 ·International Journal of Cancer ·(unknown), Carol Waghorne	16
15	Evidence that β1‐6 branched Asn‐linked oligosaccharides on metastatic tumor cells facilitate invasion of basement membranes 1989 ·International Journal of Cancer ·Simcha Yagel, Raphael Feinmesser, Carol Waghorne, Peeyush K. Lala, Martin L. Breitman, James W. Dennis	65
16	Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. 1989 ·PubMed ·Simcha Yagel, A.H. Warner, H N Nellans, Peeyush K. Lala, Carol Waghorne, David T. Denhardt	91
17	Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. 1988 ·PubMed ·Carol Waghorne, Michaël Thomas, A. Lagarde, Robert S. Kerbel, Martin L. Breitman	81
18	Analysis of Growth, Selection, and Metastasis of Tumor Cell Populations In Vivo Using Random Insertions of Foreign DNA as Genetic Tags 1988 ·Advances in experimental medicine and biology ·Carol Waghorne, Bożena Korczak, Martin L. Breitman, Robert S. Kerbel	3
19	β1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis breakdown → 1987 ·Science ·James W. Dennis, Suzanne Laferté, Carol Waghorne, Martin L. Breitman, Robert S. Kerbel	819
20	Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. 1987 ·Proceedings of the National Academy of Sciences ·Robert S. Kerbel, Carol Waghorne, (unknown), B E Elliott, Martin L. Breitman	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact